Liquidia Corporation (FRA:LT4)

Germany · Delayed Price · Currency is EUR

29.36

+0.22 (0.75%)

At close: Dec 5, 2025

176.72% (1Y)

Market Cap	2.57B
Revenue (ttm)	58.99M
Net Income (ttm)	-105.76M
Shares Out	n/a
EPS (ttm)	-1.24
PE Ratio	n/a
Forward PE	20.37
Dividend	n/a
Ex-Dividend Date	n/a

Volume	838
Average Volume	102
Open	28.94
Previous Close	29.14
Day's Range	28.94 - 29.36
52-Week Range	10.08 - 29.36
Beta	n/a
RSI	67.08
Earnings Date	Mar 16, 2026

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational ... [Read more]

Industry Pharmaceutical Preparations

Founded 2004

Employees 170

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol LT4

Full Company Profile

Financial Performance

In 2024, Liquidia's revenue was $14.00 million, a decrease of -19.97% compared to the previous year's $17.49 million. Losses were -$130.39 million, 66.1% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.